Male ≥18 years of age.

Able to Sign informed consent form independently.

Non-metastatic adenocarcinoma of the prostate.

Subjects must have as least one of the following features according to NCCN definition of high-risk: Gleason score ≥8, or PSA \>20ng/ml,or≥clinical T3a.

Subjects with pelvic lymph node involvement(N1) can be included.

Candidate for radical prostatectomy with or without pelvic lymph node dissection as per the investigator.

Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

Subjects must have normal organ and marrow function as defined below:

Hemoglobin ≥ 9.0 g/dL;Absolute neutrophil count (ANC) ≥ 1,500/mcL; Platelets ≥ 100,000/mcL, independent of transfusions/growth factors within 3 months of treatment start; Serum potassium ≥ 3.5 mmol/L; Serum total bilirubin ≤ 2.0 x upper limit of normal (ULN) (except in subjects with Gilbert's syndrome who have a total bilirubin \> 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤ 1.5 x ULN, subject may be eligible);Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN;Serum albumin ≥ 3.0 g/dL;Serum creatinine \< 2.0 x ULN.

Prostate cancer with neuroendocrine differentiation or small cell features

Distant metastasis based on conventional imaging (clinical stage M1). Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion.

History of prior systemic or local therapy for prostate cancer, including pelvic radiation for prostate cancer.

Subjects who are planning bilateral orchidectomy during the treatment period of the study.

Intolerable with darolutamide or ADT treatment.

Candidates of other clinical trials.

Any prior malignancy within 5 years.

Complications include significant cardiovascular disease, active infection, astrointestinal disorders, or any other complications that in the opinion of the investigator.

Any condition that in the opinion of the investigator would preclude participation in this study.